Preferred Label : KRAS G12C Inhibitor JMKX001899;
NCIt definition : An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C,
with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor
JMKX001899 targets and irreversibly binds to the KRAS G12C mutant, and locks it in
an inactive state. This inhibits the activity of the KRAS G12C mutant, thereby preventing
KRAS G12C mutant-mediated signaling. KRAS, a member of the RAS family of oncogenes,
serves an important role in cell signaling, division and differentiation. Mutations
of KRAS may induce constitutive signal transduction leading to tumor cell growth,
proliferation, invasion, and metastasis. JMKX001899 is able to penetrate through the
blood-brain barrier (BBB).;
Molecule name : JMKX 001899; JMKX-001899;
Origin ID : C213772;
concept_is_in_subset
- has_target
